⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AKBA News
Akebia Therapeutics, Inc.
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
globenewswire.com
AKBA
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
AKBA
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
globenewswire.com
AKBA
Form 8-K
sec.gov
AKBA
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights
globenewswire.com
AKBA
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
AKBA
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology
globenewswire.com
AKBA
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights
globenewswire.com
AKBA
Germany Anemia Treatment Market Forecast and Company Analysis Report 2026-2034 Featuring Akebia Therapeutics, GSK, Vertex, Pfizer, Sanofi, Takeda, Novartis, Johnson & Johnson, Roche, Biocon Biologics
globenewswire.com
AKBA
GSK
VRTX
PFE
SNY
NVS
JNJ
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
globenewswire.com
AKBA